The New and the Old -- Molecular Diagnostics and Hemolytic Disease of the Newborn
- 26 August 1993
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 329 (9) , 658-660
- https://doi.org/10.1056/nejm199308263290913
Abstract
Hemolytic disease of the newborn occurs as a result of sensitization of the mother's immune system to red-cell antigens of the fetus. This sensitization results from the transplacental passage of fetal red cells possessing an antigen that is not present on maternal red cells. The IgG antibodies produced by the mother in response to the foreign antigen cross the placenta into the fetal circulation, bind to the red cells there, and destroy them. As a consequence of the hemolytic process, there is both extramedullary hematopoiesis and reticuloendothelial clearance of sensitized fetal cells, leading to hepatic and splenic enlargement. As the . . .Keywords
This publication has 7 references indexed in Scilit:
- Prenatal Determination of Fetal RhD Type by DNA AmplificationNew England Journal of Medicine, 1993
- Management of fetal hemolytic disease by cordocentesisAmerican Journal of Obstetrics and Gynecology, 1991
- Epidemiology of Rh hemolytic disease of the newborn in the United StatesPublished by American Medical Association (AMA) ,1991
- Management of immune haemolytic disease in the fetusBlood Reviews, 1991
- Severe Rh isoimmunization—Current methods of in utero diagnosis and treatmentAmerican Journal of Obstetrics and Gynecology, 1988
- The evaluation of maternal anti-D concentrations during pregnancyEarly Human Development, 1987
- The management of severe rhesus isoimmunization by fetoscopic intravascular transfusionsPublished by Elsevier ,1984